Cargando…

Prenatal Screening Using Maternal Markers

Maternal markers are widely used to screen for fetal neural tube defects (NTDs), chromosomal abnormalities and cardiac defects. Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia. The methods initially developed for NTDs using a single marker ha...

Descripción completa

Detalles Bibliográficos
Autor principal: Cuckle, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449694/
https://www.ncbi.nlm.nih.gov/pubmed/26237388
http://dx.doi.org/10.3390/jcm3020504
_version_ 1782373902321713152
author Cuckle, Howard
author_facet Cuckle, Howard
author_sort Cuckle, Howard
collection PubMed
description Maternal markers are widely used to screen for fetal neural tube defects (NTDs), chromosomal abnormalities and cardiac defects. Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia. The methods initially developed for NTDs using a single marker have since been built upon to develop high performance multi-maker tests for chromosomal abnormalities. Although cell-free DNA testing is still too expensive to be considered for routine application in public health settings, it can be cost-effective when used in combination with existing multi-maker marker tests. The established screening methods can be readily applied in the first trimester to identify pregnancies at high risk of pre-eclampsia and offer prevention though aspirin treatment. Prenatal screening for fragile X syndrome might be adopted more widely if the test was to be framed as a form of maternal marker screening.
format Online
Article
Text
id pubmed-4449694
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44496942015-07-28 Prenatal Screening Using Maternal Markers Cuckle, Howard J Clin Med Review Maternal markers are widely used to screen for fetal neural tube defects (NTDs), chromosomal abnormalities and cardiac defects. Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia. The methods initially developed for NTDs using a single marker have since been built upon to develop high performance multi-maker tests for chromosomal abnormalities. Although cell-free DNA testing is still too expensive to be considered for routine application in public health settings, it can be cost-effective when used in combination with existing multi-maker marker tests. The established screening methods can be readily applied in the first trimester to identify pregnancies at high risk of pre-eclampsia and offer prevention though aspirin treatment. Prenatal screening for fragile X syndrome might be adopted more widely if the test was to be framed as a form of maternal marker screening. MDPI 2014-05-09 /pmc/articles/PMC4449694/ /pubmed/26237388 http://dx.doi.org/10.3390/jcm3020504 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Cuckle, Howard
Prenatal Screening Using Maternal Markers
title Prenatal Screening Using Maternal Markers
title_full Prenatal Screening Using Maternal Markers
title_fullStr Prenatal Screening Using Maternal Markers
title_full_unstemmed Prenatal Screening Using Maternal Markers
title_short Prenatal Screening Using Maternal Markers
title_sort prenatal screening using maternal markers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449694/
https://www.ncbi.nlm.nih.gov/pubmed/26237388
http://dx.doi.org/10.3390/jcm3020504
work_keys_str_mv AT cucklehoward prenatalscreeningusingmaternalmarkers